Goreisan suppresses cardiac remodeling and dysfunction in a new mouse model with diabetic cardiomyopathy.

BACKGROUND

The global increase in diabetes, driven by aging populations and lifestyle changes, has led to an increase in the incidence of diabetic cardiomyopathy (DCM). DCM is characterized by metabolic abnormalities, oxidative stress, and inflammation, leading to cardiac remodeling and dysfunction. Goreisan (GRS), a traditional Japanese Kampo medicine, is commonly used to treat fluid control such as edema, due to its diuretic effect. In this study, we examined the effects of GRS on DCM.

METHODS

We first established a new mouse model of DCM and then evaluated the effects of GRS on DCM using a recently developed model.

RESULTS

The DCM mouse model developed cardiac hypertrophy, fibrosis, and dysfunction by nine weeks, which was ameliorated by GRS administration. GRS suppressed apoptosis and protein degradation by inhibiting Akt dephosphorylation and oxidative stress in DCM mice. In contrast, no differences in inflammatory cytokine levels were observed, regardless of GRS administration.

CONCLUSION

GRS has potential efficacy in preventing DCM onset and development.